nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—HRH1—atherosclerosis	0.537	1	CbGaD
Maprotiline—CYP2D6—Niacin—atherosclerosis	0.0314	0.149	CbGbCtD
Maprotiline—ABCB1—Ezetimibe—atherosclerosis	0.0283	0.134	CbGbCtD
Maprotiline—ABCB1—Simvastatin—atherosclerosis	0.0263	0.125	CbGbCtD
Maprotiline—ABCB1—Pravastatin—atherosclerosis	0.0257	0.122	CbGbCtD
Maprotiline—ABCB1—Lovastatin—atherosclerosis	0.0257	0.122	CbGbCtD
Maprotiline—CYP2D6—Simvastatin—atherosclerosis	0.0248	0.118	CbGbCtD
Maprotiline—CYP2D6—Pravastatin—atherosclerosis	0.0243	0.115	CbGbCtD
Maprotiline—CYP2D6—Lovastatin—atherosclerosis	0.0243	0.115	CbGbCtD
Maprotiline—HTR2A—arteriole—atherosclerosis	0.00297	0.149	CbGeAlD
Maprotiline—HTR7—vein—atherosclerosis	0.00284	0.142	CbGeAlD
Maprotiline—HTR2A—vein—atherosclerosis	0.00177	0.0888	CbGeAlD
Maprotiline—HTR2A—hindlimb—atherosclerosis	0.00118	0.059	CbGeAlD
Maprotiline—HTR7—artery—atherosclerosis	0.00116	0.058	CbGeAlD
Maprotiline—HTR2A—appendage—atherosclerosis	0.00101	0.0506	CbGeAlD
Maprotiline—HTR7—endothelium—atherosclerosis	0.000977	0.049	CbGeAlD
Maprotiline—HTR7—blood vessel—atherosclerosis	0.000901	0.0452	CbGeAlD
Maprotiline—HTR2A—artery—atherosclerosis	0.000721	0.0362	CbGeAlD
Maprotiline—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.000695	0.00482	CcSEcCtD
Maprotiline—Eosinophilia—Lovastatin—atherosclerosis	0.000691	0.00479	CcSEcCtD
Maprotiline—Disturbance in sexual arousal—Niacin—atherosclerosis	0.000688	0.00477	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Simvastatin—atherosclerosis	0.00068	0.00472	CcSEcCtD
Maprotiline—Eosinophilia—Ezetimibe—atherosclerosis	0.000678	0.0047	CcSEcCtD
Maprotiline—Muscular weakness—Simvastatin—atherosclerosis	0.000666	0.00462	CcSEcCtD
Maprotiline—Urinary retention—Niacin—atherosclerosis	0.00066	0.00458	CcSEcCtD
Maprotiline—Hepatitis—Rosuvastatin—atherosclerosis	0.000659	0.00457	CcSEcCtD
Maprotiline—Eosinophilia—Simvastatin—atherosclerosis	0.000647	0.00449	CcSEcCtD
Maprotiline—Erectile dysfunction—Lovastatin—atherosclerosis	0.000643	0.00446	CcSEcCtD
Maprotiline—Liver function test abnormal—Niacin—atherosclerosis	0.000641	0.00444	CcSEcCtD
Maprotiline—Photosensitivity reaction—Lovastatin—atherosclerosis	0.000637	0.00442	CcSEcCtD
Maprotiline—Orthostatic hypotension—Niacin—atherosclerosis	0.000634	0.0044	CcSEcCtD
Maprotiline—Erectile dysfunction—Ezetimibe—atherosclerosis	0.000631	0.00437	CcSEcCtD
Maprotiline—Liver function test abnormal—Pravastatin—atherosclerosis	0.000631	0.00437	CcSEcCtD
Maprotiline—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.000625	0.00434	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Lovastatin—atherosclerosis	0.000617	0.00428	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Pravastatin—atherosclerosis	0.000615	0.00427	CcSEcCtD
Maprotiline—Muscular weakness—Niacin—atherosclerosis	0.000612	0.00424	CcSEcCtD
Maprotiline—Infestation NOS—Ezetimibe—atherosclerosis	0.000611	0.00424	CcSEcCtD
Maprotiline—Infestation—Ezetimibe—atherosclerosis	0.000611	0.00424	CcSEcCtD
Maprotiline—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00061	0.00423	CcSEcCtD
Maprotiline—HTR2A—endothelium—atherosclerosis	0.000609	0.0306	CbGeAlD
Maprotiline—Muscular weakness—Pravastatin—atherosclerosis	0.000603	0.00418	CcSEcCtD
Maprotiline—Erectile dysfunction—Simvastatin—atherosclerosis	0.000602	0.00417	CcSEcCtD
Maprotiline—Dysphagia—Niacin—atherosclerosis	0.0006	0.00416	CcSEcCtD
Maprotiline—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.000599	0.00415	CcSEcCtD
Maprotiline—Photosensitivity reaction—Simvastatin—atherosclerosis	0.000596	0.00413	CcSEcCtD
Maprotiline—Jaundice—Ezetimibe—atherosclerosis	0.000595	0.00413	CcSEcCtD
Maprotiline—Arrhythmia—Rosuvastatin—atherosclerosis	0.000589	0.00409	CcSEcCtD
Maprotiline—Eosinophilia—Pravastatin—atherosclerosis	0.000585	0.00405	CcSEcCtD
Maprotiline—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000577	0.00401	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Simvastatin—atherosclerosis	0.000577	0.004	CcSEcCtD
Maprotiline—Sweating increased—Pravastatin—atherosclerosis	0.000575	0.00399	CcSEcCtD
Maprotiline—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000571	0.00396	CcSEcCtD
Maprotiline—Jaundice—Simvastatin—atherosclerosis	0.000568	0.00394	CcSEcCtD
Maprotiline—HTR2A—blood vessel—atherosclerosis	0.000562	0.0282	CbGeAlD
Maprotiline—Hepatitis—Lovastatin—atherosclerosis	0.000559	0.00388	CcSEcCtD
Maprotiline—Erectile dysfunction—Niacin—atherosclerosis	0.000552	0.00383	CcSEcCtD
Maprotiline—Hepatitis—Ezetimibe—atherosclerosis	0.000548	0.0038	CcSEcCtD
Maprotiline—Erectile dysfunction—Pravastatin—atherosclerosis	0.000544	0.00377	CcSEcCtD
Maprotiline—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000539	0.00374	CcSEcCtD
Maprotiline—Weight increased—Pravastatin—atherosclerosis	0.000537	0.00373	CcSEcCtD
Maprotiline—Weight decreased—Pravastatin—atherosclerosis	0.000534	0.00371	CcSEcCtD
Maprotiline—Erythema multiforme—Lovastatin—atherosclerosis	0.000528	0.00367	CcSEcCtD
Maprotiline—Hepatitis—Simvastatin—atherosclerosis	0.000523	0.00363	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Pravastatin—atherosclerosis	0.000522	0.00362	CcSEcCtD
Maprotiline—Stomatitis—Niacin—atherosclerosis	0.000521	0.00361	CcSEcCtD
Maprotiline—Jaundice—Niacin—atherosclerosis	0.000521	0.00361	CcSEcCtD
Maprotiline—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000519	0.0036	CcSEcCtD
Maprotiline—Flushing—Lovastatin—atherosclerosis	0.000519	0.0036	CcSEcCtD
Maprotiline—CHRM2—cardiovascular system—atherosclerosis	0.000518	0.026	CbGeAlD
Maprotiline—Erythema multiforme—Ezetimibe—atherosclerosis	0.000518	0.00359	CcSEcCtD
Maprotiline—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000516	0.00358	CcSEcCtD
Maprotiline—Myocardial infarction—Pravastatin—atherosclerosis	0.000516	0.00358	CcSEcCtD
Maprotiline—Jaundice—Pravastatin—atherosclerosis	0.000513	0.00356	CcSEcCtD
Maprotiline—Flushing—Ezetimibe—atherosclerosis	0.000509	0.00353	CcSEcCtD
Maprotiline—Angiopathy—Ezetimibe—atherosclerosis	0.000497	0.00345	CcSEcCtD
Maprotiline—Erythema multiforme—Simvastatin—atherosclerosis	0.000494	0.00343	CcSEcCtD
Maprotiline—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000494	0.00343	CcSEcCtD
Maprotiline—Alopecia—Lovastatin—atherosclerosis	0.000494	0.00343	CcSEcCtD
Maprotiline—Nortriptyline—HRH1—atherosclerosis	0.000489	0.363	CrCbGaD
Maprotiline—Flushing—Simvastatin—atherosclerosis	0.000485	0.00337	CcSEcCtD
Maprotiline—Alopecia—Ezetimibe—atherosclerosis	0.000484	0.00336	CcSEcCtD
Maprotiline—Hepatitis—Niacin—atherosclerosis	0.00048	0.00333	CcSEcCtD
Maprotiline—Hypoaesthesia—Niacin—atherosclerosis	0.000478	0.00331	CcSEcCtD
Maprotiline—Malnutrition—Ezetimibe—atherosclerosis	0.000477	0.00331	CcSEcCtD
Maprotiline—Dysgeusia—Lovastatin—atherosclerosis	0.000476	0.0033	CcSEcCtD
Maprotiline—Hepatitis—Pravastatin—atherosclerosis	0.000473	0.00328	CcSEcCtD
Maprotiline—Confusional state—Rosuvastatin—atherosclerosis	0.000472	0.00328	CcSEcCtD
Maprotiline—CHRM1—cardiovascular system—atherosclerosis	0.000472	0.0237	CbGeAlD
Maprotiline—Hypoaesthesia—Pravastatin—atherosclerosis	0.00047	0.00326	CcSEcCtD
Maprotiline—Infection—Rosuvastatin—atherosclerosis	0.000465	0.00323	CcSEcCtD
Maprotiline—Alopecia—Simvastatin—atherosclerosis	0.000462	0.0032	CcSEcCtD
Maprotiline—HTR7—connective tissue—atherosclerosis	0.000462	0.0232	CbGeAlD
Maprotiline—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000459	0.00319	CcSEcCtD
Maprotiline—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000459	0.00318	CcSEcCtD
Maprotiline—Vision blurred—Lovastatin—atherosclerosis	0.000459	0.00318	CcSEcCtD
Maprotiline—Tremor—Lovastatin—atherosclerosis	0.000456	0.00316	CcSEcCtD
Maprotiline—Eye disorder—Niacin—atherosclerosis	0.000449	0.00311	CcSEcCtD
Maprotiline—Tinnitus—Niacin—atherosclerosis	0.000448	0.0031	CcSEcCtD
Maprotiline—Erythema multiforme—Pravastatin—atherosclerosis	0.000447	0.0031	CcSEcCtD
Maprotiline—Dysgeusia—Simvastatin—atherosclerosis	0.000446	0.00309	CcSEcCtD
Maprotiline—Flushing—Niacin—atherosclerosis	0.000445	0.00309	CcSEcCtD
Maprotiline—Tinnitus—Pravastatin—atherosclerosis	0.000441	0.00306	CcSEcCtD
Maprotiline—Cardiac disorder—Pravastatin—atherosclerosis	0.000439	0.00304	CcSEcCtD
Maprotiline—Flushing—Pravastatin—atherosclerosis	0.000439	0.00304	CcSEcCtD
Maprotiline—Angiopathy—Niacin—atherosclerosis	0.000435	0.00302	CcSEcCtD
Maprotiline—Leukopenia—Lovastatin—atherosclerosis	0.000435	0.00302	CcSEcCtD
Maprotiline—Vision blurred—Simvastatin—atherosclerosis	0.000429	0.00297	CcSEcCtD
Maprotiline—Arrhythmia—Niacin—atherosclerosis	0.000429	0.00297	CcSEcCtD
Maprotiline—Tremor—Simvastatin—atherosclerosis	0.000426	0.00296	CcSEcCtD
Maprotiline—Alopecia—Niacin—atherosclerosis	0.000424	0.00294	CcSEcCtD
Maprotiline—Insomnia—Rosuvastatin—atherosclerosis	0.000424	0.00294	CcSEcCtD
Maprotiline—Arrhythmia—Pravastatin—atherosclerosis	0.000422	0.00293	CcSEcCtD
Maprotiline—Palpitations—Ezetimibe—atherosclerosis	0.000422	0.00292	CcSEcCtD
Maprotiline—Paraesthesia—Rosuvastatin—atherosclerosis	0.000421	0.00292	CcSEcCtD
Maprotiline—Malnutrition—Niacin—atherosclerosis	0.000418	0.0029	CcSEcCtD
Maprotiline—Alopecia—Pravastatin—atherosclerosis	0.000418	0.0029	CcSEcCtD
Maprotiline—Anxiety—Lovastatin—atherosclerosis	0.000413	0.00286	CcSEcCtD
Maprotiline—Dyspepsia—Rosuvastatin—atherosclerosis	0.000412	0.00286	CcSEcCtD
Maprotiline—Hypertension—Ezetimibe—atherosclerosis	0.000412	0.00286	CcSEcCtD
Maprotiline—Tension—Niacin—atherosclerosis	0.00041	0.00284	CcSEcCtD
Maprotiline—Leukopenia—Simvastatin—atherosclerosis	0.000407	0.00283	CcSEcCtD
Maprotiline—Nervousness—Niacin—atherosclerosis	0.000406	0.00281	CcSEcCtD
Maprotiline—Dry mouth—Lovastatin—atherosclerosis	0.000405	0.00281	CcSEcCtD
Maprotiline—Tension—Pravastatin—atherosclerosis	0.000404	0.0028	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000403	0.0028	CcSEcCtD
Maprotiline—Desipramine—HRH1—atherosclerosis	0.000403	0.299	CrCbGaD
Maprotiline—Dysgeusia—Pravastatin—atherosclerosis	0.000403	0.00279	CcSEcCtD
Maprotiline—HTR7—cardiovascular system—atherosclerosis	0.000402	0.0202	CbGeAlD
Maprotiline—Constipation—Rosuvastatin—atherosclerosis	0.000401	0.00278	CcSEcCtD
Maprotiline—Confusional state—Lovastatin—atherosclerosis	0.0004	0.00278	CcSEcCtD
Maprotiline—Nervousness—Pravastatin—atherosclerosis	0.0004	0.00277	CcSEcCtD
Maprotiline—Dry mouth—Ezetimibe—atherosclerosis	0.000397	0.00276	CcSEcCtD
Maprotiline—Infection—Lovastatin—atherosclerosis	0.000394	0.00274	CcSEcCtD
Maprotiline—Vision blurred—Niacin—atherosclerosis	0.000394	0.00273	CcSEcCtD
Maprotiline—Confusional state—Ezetimibe—atherosclerosis	0.000393	0.00272	CcSEcCtD
Maprotiline—Thrombocytopenia—Lovastatin—atherosclerosis	0.000389	0.0027	CcSEcCtD
Maprotiline—Vision blurred—Pravastatin—atherosclerosis	0.000388	0.00269	CcSEcCtD
Maprotiline—Infection—Ezetimibe—atherosclerosis	0.000387	0.00268	CcSEcCtD
Maprotiline—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000386	0.00268	CcSEcCtD
Maprotiline—Anxiety—Simvastatin—atherosclerosis	0.000386	0.00268	CcSEcCtD
Maprotiline—Tremor—Pravastatin—atherosclerosis	0.000385	0.00267	CcSEcCtD
Maprotiline—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000383	0.00266	CcSEcCtD
Maprotiline—Nervous system disorder—Ezetimibe—atherosclerosis	0.000382	0.00265	CcSEcCtD
Maprotiline—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000381	0.00264	CcSEcCtD
Maprotiline—Skin disorder—Ezetimibe—atherosclerosis	0.000378	0.00262	CcSEcCtD
Maprotiline—Syncope—Niacin—atherosclerosis	0.000375	0.0026	CcSEcCtD
Maprotiline—Confusional state—Simvastatin—atherosclerosis	0.000374	0.0026	CcSEcCtD
Maprotiline—Leukopenia—Niacin—atherosclerosis	0.000374	0.00259	CcSEcCtD
Maprotiline—CHRM3—adipose tissue—atherosclerosis	0.000372	0.0187	CbGeAlD
Maprotiline—Urticaria—Rosuvastatin—atherosclerosis	0.000372	0.00258	CcSEcCtD
Maprotiline—Oedema—Simvastatin—atherosclerosis	0.000371	0.00258	CcSEcCtD
Maprotiline—Abdominal pain—Rosuvastatin—atherosclerosis	0.00037	0.00257	CcSEcCtD
Maprotiline—Palpitations—Niacin—atherosclerosis	0.000369	0.00256	CcSEcCtD
Maprotiline—Infection—Simvastatin—atherosclerosis	0.000369	0.00256	CcSEcCtD
Maprotiline—Leukopenia—Pravastatin—atherosclerosis	0.000368	0.00255	CcSEcCtD
Maprotiline—ABCB1—blood vessel—atherosclerosis	0.000368	0.0185	CbGeAlD
Maprotiline—Loss of consciousness—Niacin—atherosclerosis	0.000367	0.00255	CcSEcCtD
Maprotiline—Thrombocytopenia—Simvastatin—atherosclerosis	0.000364	0.00252	CcSEcCtD
Maprotiline—Insomnia—Lovastatin—atherosclerosis	0.000359	0.00249	CcSEcCtD
Maprotiline—Paraesthesia—Lovastatin—atherosclerosis	0.000357	0.00247	CcSEcCtD
Maprotiline—Hypertension—Pravastatin—atherosclerosis	0.000355	0.00246	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000353	0.00245	CcSEcCtD
Maprotiline—Insomnia—Ezetimibe—atherosclerosis	0.000352	0.00244	CcSEcCtD
Maprotiline—Paraesthesia—Ezetimibe—atherosclerosis	0.00035	0.00243	CcSEcCtD
Maprotiline—Dyspepsia—Lovastatin—atherosclerosis	0.00035	0.00242	CcSEcCtD
Maprotiline—Anxiety—Pravastatin—atherosclerosis	0.000349	0.00242	CcSEcCtD
Maprotiline—Dry mouth—Niacin—atherosclerosis	0.000348	0.00241	CcSEcCtD
Maprotiline—HRH1—connective tissue—atherosclerosis	0.000345	0.0173	CbGeAlD
Maprotiline—ORM1—liver—atherosclerosis	0.000344	0.0173	CbGeAlD
Maprotiline—Dyspepsia—Ezetimibe—atherosclerosis	0.000343	0.00238	CcSEcCtD
Maprotiline—Fatigue—Lovastatin—atherosclerosis	0.000342	0.00237	CcSEcCtD
Maprotiline—Imipramine—HRH1—atherosclerosis	0.000342	0.254	CrCbGaD
Maprotiline—Oedema—Niacin—atherosclerosis	0.000341	0.00237	CcSEcCtD
Maprotiline—Constipation—Lovastatin—atherosclerosis	0.00034	0.00236	CcSEcCtD
Maprotiline—Confusional state—Pravastatin—atherosclerosis	0.000339	0.00235	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000336	0.00233	CcSEcCtD
Maprotiline—Asthenia—Rosuvastatin—atherosclerosis	0.000336	0.00233	CcSEcCtD
Maprotiline—Insomnia—Simvastatin—atherosclerosis	0.000336	0.00233	CcSEcCtD
Maprotiline—Oedema—Pravastatin—atherosclerosis	0.000336	0.00233	CcSEcCtD
Maprotiline—Fatigue—Ezetimibe—atherosclerosis	0.000336	0.00233	CcSEcCtD
Maprotiline—Shock—Niacin—atherosclerosis	0.000336	0.00233	CcSEcCtD
Maprotiline—Infection—Pravastatin—atherosclerosis	0.000334	0.00231	CcSEcCtD
Maprotiline—Paraesthesia—Simvastatin—atherosclerosis	0.000333	0.00231	CcSEcCtD
Maprotiline—Constipation—Ezetimibe—atherosclerosis	0.000333	0.00231	CcSEcCtD
Maprotiline—Tachycardia—Niacin—atherosclerosis	0.000333	0.00231	CcSEcCtD
Maprotiline—Pruritus—Rosuvastatin—atherosclerosis	0.000331	0.0023	CcSEcCtD
Maprotiline—Skin disorder—Niacin—atherosclerosis	0.000331	0.0023	CcSEcCtD
Maprotiline—Hyperhidrosis—Niacin—atherosclerosis	0.00033	0.00229	CcSEcCtD
Maprotiline—Thrombocytopenia—Pravastatin—atherosclerosis	0.000329	0.00228	CcSEcCtD
Maprotiline—Feeling abnormal—Lovastatin—atherosclerosis	0.000327	0.00227	CcSEcCtD
Maprotiline—Dyspepsia—Simvastatin—atherosclerosis	0.000327	0.00227	CcSEcCtD
Maprotiline—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000325	0.00225	CcSEcCtD
Maprotiline—Hyperhidrosis—Pravastatin—atherosclerosis	0.000325	0.00225	CcSEcCtD
Maprotiline—Feeling abnormal—Ezetimibe—atherosclerosis	0.000321	0.00223	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000321	0.00222	CcSEcCtD
Maprotiline—Diarrhoea—Rosuvastatin—atherosclerosis	0.000321	0.00222	CcSEcCtD
Maprotiline—Fatigue—Simvastatin—atherosclerosis	0.00032	0.00222	CcSEcCtD
Maprotiline—Hypotension—Niacin—atherosclerosis	0.000319	0.00221	CcSEcCtD
Maprotiline—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000318	0.00221	CcSEcCtD
Maprotiline—Constipation—Simvastatin—atherosclerosis	0.000318	0.0022	CcSEcCtD
Maprotiline—Urticaria—Lovastatin—atherosclerosis	0.000315	0.00219	CcSEcCtD
Maprotiline—Body temperature increased—Lovastatin—atherosclerosis	0.000314	0.00218	CcSEcCtD
Maprotiline—Abdominal pain—Lovastatin—atherosclerosis	0.000314	0.00218	CcSEcCtD
Maprotiline—Dizziness—Rosuvastatin—atherosclerosis	0.00031	0.00215	CcSEcCtD
Maprotiline—Urticaria—Ezetimibe—atherosclerosis	0.000309	0.00215	CcSEcCtD
Maprotiline—Insomnia—Niacin—atherosclerosis	0.000308	0.00214	CcSEcCtD
Maprotiline—Body temperature increased—Ezetimibe—atherosclerosis	0.000308	0.00214	CcSEcCtD
Maprotiline—Abdominal pain—Ezetimibe—atherosclerosis	0.000308	0.00214	CcSEcCtD
Maprotiline—Paraesthesia—Niacin—atherosclerosis	0.000306	0.00212	CcSEcCtD
Maprotiline—Feeling abnormal—Simvastatin—atherosclerosis	0.000306	0.00212	CcSEcCtD
Maprotiline—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000304	0.00211	CcSEcCtD
Maprotiline—Insomnia—Pravastatin—atherosclerosis	0.000304	0.00211	CcSEcCtD
Maprotiline—Somnolence—Niacin—atherosclerosis	0.000303	0.0021	CcSEcCtD
Maprotiline—Paraesthesia—Pravastatin—atherosclerosis	0.000302	0.00209	CcSEcCtD
Maprotiline—Dyspepsia—Niacin—atherosclerosis	0.0003	0.00208	CcSEcCtD
Maprotiline—Dyspepsia—Pravastatin—atherosclerosis	0.000296	0.00205	CcSEcCtD
Maprotiline—Rash—Rosuvastatin—atherosclerosis	0.000295	0.00205	CcSEcCtD
Maprotiline—Dermatitis—Rosuvastatin—atherosclerosis	0.000295	0.00205	CcSEcCtD
Maprotiline—Urticaria—Simvastatin—atherosclerosis	0.000295	0.00205	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Niacin—atherosclerosis	0.000294	0.00204	CcSEcCtD
Maprotiline—Body temperature increased—Simvastatin—atherosclerosis	0.000294	0.00204	CcSEcCtD
Maprotiline—Abdominal pain—Simvastatin—atherosclerosis	0.000294	0.00204	CcSEcCtD
Maprotiline—Headache—Rosuvastatin—atherosclerosis	0.000294	0.00204	CcSEcCtD
Maprotiline—Fatigue—Pravastatin—atherosclerosis	0.000289	0.00201	CcSEcCtD
Maprotiline—HTR2A—connective tissue—atherosclerosis	0.000288	0.0145	CbGeAlD
Maprotiline—Constipation—Pravastatin—atherosclerosis	0.000287	0.00199	CcSEcCtD
Maprotiline—Asthenia—Lovastatin—atherosclerosis	0.000285	0.00198	CcSEcCtD
Maprotiline—Pruritus—Lovastatin—atherosclerosis	0.000281	0.00195	CcSEcCtD
Maprotiline—Asthenia—Ezetimibe—atherosclerosis	0.000279	0.00194	CcSEcCtD
Maprotiline—Gastrointestinal pain—Niacin—atherosclerosis	0.000279	0.00193	CcSEcCtD
Maprotiline—Nausea—Rosuvastatin—atherosclerosis	0.000278	0.00193	CcSEcCtD
Maprotiline—Feeling abnormal—Pravastatin—atherosclerosis	0.000277	0.00192	CcSEcCtD
Maprotiline—Pruritus—Ezetimibe—atherosclerosis	0.000276	0.00191	CcSEcCtD
Maprotiline—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000275	0.0019	CcSEcCtD
Maprotiline—Diarrhoea—Lovastatin—atherosclerosis	0.000272	0.00188	CcSEcCtD
Maprotiline—Urticaria—Niacin—atherosclerosis	0.000271	0.00188	CcSEcCtD
Maprotiline—Abdominal pain—Niacin—atherosclerosis	0.00027	0.00187	CcSEcCtD
Maprotiline—Body temperature increased—Niacin—atherosclerosis	0.00027	0.00187	CcSEcCtD
Maprotiline—Urticaria—Pravastatin—atherosclerosis	0.000267	0.00185	CcSEcCtD
Maprotiline—Asthenia—Simvastatin—atherosclerosis	0.000266	0.00185	CcSEcCtD
Maprotiline—Diarrhoea—Ezetimibe—atherosclerosis	0.000266	0.00185	CcSEcCtD
Maprotiline—Abdominal pain—Pravastatin—atherosclerosis	0.000265	0.00184	CcSEcCtD
Maprotiline—Body temperature increased—Pravastatin—atherosclerosis	0.000265	0.00184	CcSEcCtD
Maprotiline—HRH1—adipose tissue—atherosclerosis	0.000265	0.0133	CbGeAlD
Maprotiline—Pruritus—Simvastatin—atherosclerosis	0.000263	0.00182	CcSEcCtD
Maprotiline—Dizziness—Lovastatin—atherosclerosis	0.000263	0.00182	CcSEcCtD
Maprotiline—Dizziness—Ezetimibe—atherosclerosis	0.000258	0.00179	CcSEcCtD
Maprotiline—Diarrhoea—Simvastatin—atherosclerosis	0.000254	0.00176	CcSEcCtD
Maprotiline—Vomiting—Lovastatin—atherosclerosis	0.000252	0.00175	CcSEcCtD
Maprotiline—HTR2A—cardiovascular system—atherosclerosis	0.000251	0.0126	CbGeAlD
Maprotiline—Rash—Lovastatin—atherosclerosis	0.00025	0.00174	CcSEcCtD
Maprotiline—Dermatitis—Lovastatin—atherosclerosis	0.00025	0.00173	CcSEcCtD
Maprotiline—Headache—Lovastatin—atherosclerosis	0.000249	0.00173	CcSEcCtD
Maprotiline—HTR7—liver—atherosclerosis	0.000249	0.0125	CbGeAlD
Maprotiline—Vomiting—Ezetimibe—atherosclerosis	0.000248	0.00172	CcSEcCtD
Maprotiline—Dizziness—Simvastatin—atherosclerosis	0.000246	0.0017	CcSEcCtD
Maprotiline—Rash—Ezetimibe—atherosclerosis	0.000246	0.0017	CcSEcCtD
Maprotiline—Dermatitis—Ezetimibe—atherosclerosis	0.000245	0.0017	CcSEcCtD
Maprotiline—Asthenia—Niacin—atherosclerosis	0.000245	0.0017	CcSEcCtD
Maprotiline—Headache—Ezetimibe—atherosclerosis	0.000244	0.00169	CcSEcCtD
Maprotiline—Pruritus—Niacin—atherosclerosis	0.000241	0.00167	CcSEcCtD
Maprotiline—Asthenia—Pravastatin—atherosclerosis	0.000241	0.00167	CcSEcCtD
Maprotiline—Pruritus—Pravastatin—atherosclerosis	0.000238	0.00165	CcSEcCtD
Maprotiline—Vomiting—Simvastatin—atherosclerosis	0.000236	0.00164	CcSEcCtD
Maprotiline—Nausea—Lovastatin—atherosclerosis	0.000236	0.00164	CcSEcCtD
Maprotiline—Rash—Simvastatin—atherosclerosis	0.000234	0.00162	CcSEcCtD
Maprotiline—Dermatitis—Simvastatin—atherosclerosis	0.000234	0.00162	CcSEcCtD
Maprotiline—Diarrhoea—Niacin—atherosclerosis	0.000233	0.00162	CcSEcCtD
Maprotiline—Headache—Simvastatin—atherosclerosis	0.000233	0.00161	CcSEcCtD
Maprotiline—Nausea—Ezetimibe—atherosclerosis	0.000231	0.0016	CcSEcCtD
Maprotiline—Diarrhoea—Pravastatin—atherosclerosis	0.00023	0.00159	CcSEcCtD
Maprotiline—Dizziness—Niacin—atherosclerosis	0.000226	0.00156	CcSEcCtD
Maprotiline—Dizziness—Pravastatin—atherosclerosis	0.000222	0.00154	CcSEcCtD
Maprotiline—Nausea—Simvastatin—atherosclerosis	0.000221	0.00153	CcSEcCtD
Maprotiline—Vomiting—Niacin—atherosclerosis	0.000217	0.0015	CcSEcCtD
Maprotiline—Rash—Niacin—atherosclerosis	0.000215	0.00149	CcSEcCtD
Maprotiline—Dermatitis—Niacin—atherosclerosis	0.000215	0.00149	CcSEcCtD
Maprotiline—Headache—Niacin—atherosclerosis	0.000214	0.00148	CcSEcCtD
Maprotiline—Vomiting—Pravastatin—atherosclerosis	0.000213	0.00148	CcSEcCtD
Maprotiline—Rash—Pravastatin—atherosclerosis	0.000212	0.00147	CcSEcCtD
Maprotiline—Dermatitis—Pravastatin—atherosclerosis	0.000212	0.00147	CcSEcCtD
Maprotiline—Headache—Pravastatin—atherosclerosis	0.00021	0.00146	CcSEcCtD
Maprotiline—Nausea—Niacin—atherosclerosis	0.000203	0.0014	CcSEcCtD
Maprotiline—Nausea—Pravastatin—atherosclerosis	0.000199	0.00138	CcSEcCtD
Maprotiline—CYP1A2—liver—atherosclerosis	0.000198	0.00995	CbGeAlD
Maprotiline—ABCB1—cardiovascular system—atherosclerosis	0.000164	0.00824	CbGeAlD
Maprotiline—HTR2A—liver—atherosclerosis	0.000155	0.00778	CbGeAlD
Maprotiline—ABCB1—adipose tissue—atherosclerosis	0.000145	0.00727	CbGeAlD
Maprotiline—CYP2D6—liver—atherosclerosis	0.000141	0.00709	CbGeAlD
Maprotiline—Nortriptyline—ALB—atherosclerosis	0.000113	0.0839	CrCbGaD
Maprotiline—ABCB1—liver—atherosclerosis	0.000102	0.0051	CbGeAlD
Maprotiline—CHRM4—Signaling Pathways—CXCL8—atherosclerosis	6.02e-06	6.96e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—APOA1—atherosclerosis	6.02e-06	6.96e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CAV1—atherosclerosis	5.97e-06	6.91e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—APOA1—atherosclerosis	5.96e-06	6.89e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—ESR1—atherosclerosis	5.96e-06	6.89e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCL2—atherosclerosis	5.94e-06	6.88e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—F2—atherosclerosis	5.88e-06	6.81e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—ESR1—atherosclerosis	5.86e-06	6.78e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—ESR1—atherosclerosis	5.85e-06	6.77e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IGF1—atherosclerosis	5.84e-06	6.76e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—ESR1—atherosclerosis	5.83e-06	6.75e-05	CbGpPWpGaD
Maprotiline—CHRM4—GPCR downstream signaling—AKT1—atherosclerosis	5.81e-06	6.73e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—ESR1—atherosclerosis	5.81e-06	6.72e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—F2—atherosclerosis	5.79e-06	6.7e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—F2—atherosclerosis	5.78e-06	6.68e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—APOB—atherosclerosis	5.77e-06	6.68e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MMP9—atherosclerosis	5.76e-06	6.67e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—CXCL8—atherosclerosis	5.76e-06	6.67e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—F2—atherosclerosis	5.76e-06	6.66e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—ESR1—atherosclerosis	5.75e-06	6.66e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—F2—atherosclerosis	5.74e-06	6.64e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—IL6—atherosclerosis	5.72e-06	6.62e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—NFKB1—atherosclerosis	5.7e-06	6.6e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—ALB—atherosclerosis	5.7e-06	6.6e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—F2—atherosclerosis	5.68e-06	6.58e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—HMOX1—atherosclerosis	5.68e-06	6.57e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	5.67e-06	6.56e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	5.63e-06	6.51e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GSTM1—atherosclerosis	5.61e-06	6.5e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ABCA1—atherosclerosis	5.61e-06	6.49e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MAPK8—atherosclerosis	5.61e-06	6.49e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling by GPCR—AKT1—atherosclerosis	5.59e-06	6.47e-05	CbGpPWpGaD
Maprotiline—CHRM5—GPCR downstream signaling—AKT1—atherosclerosis	5.57e-06	6.44e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	5.55e-06	6.42e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	5.54e-06	6.41e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	5.53e-06	6.4e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	5.51e-06	6.38e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—LPL—atherosclerosis	5.51e-06	6.38e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CG—atherosclerosis	5.49e-06	6.36e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—IL6—atherosclerosis	5.48e-06	6.34e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—NOS3—atherosclerosis	5.45e-06	6.31e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MMP9—atherosclerosis	5.44e-06	6.3e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CG—atherosclerosis	5.44e-06	6.29e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOB—atherosclerosis	5.44e-06	6.29e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	5.39e-06	6.24e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NFKB1—atherosclerosis	5.39e-06	6.23e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—GPX1—atherosclerosis	5.38e-06	6.22e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—INS—atherosclerosis	5.33e-06	6.17e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	5.31e-06	6.14e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NOS3—atherosclerosis	5.3e-06	6.13e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	5.29e-06	6.13e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MAPK8—atherosclerosis	5.29e-06	6.12e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.29e-06	6.12e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling by GPCR—AKT1—atherosclerosis	5.28e-06	6.11e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	5.28e-06	6.11e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—MAPK3—atherosclerosis	5.26e-06	6.09e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—INS—atherosclerosis	5.24e-06	6.07e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCL2—atherosclerosis	5.24e-06	6.07e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CD36—atherosclerosis	5.24e-06	6.06e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—INS—atherosclerosis	5.23e-06	6.05e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—INS—atherosclerosis	5.22e-06	6.04e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MMP9—atherosclerosis	5.21e-06	6.03e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—MAPK3—atherosclerosis	5.21e-06	6.03e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—INS—atherosclerosis	5.2e-06	6.02e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—LPL—atherosclerosis	5.19e-06	6.01e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—VEGFA—atherosclerosis	5.18e-06	5.99e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCL2—atherosclerosis	5.16e-06	5.97e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NFKB1—atherosclerosis	5.16e-06	5.97e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IGF1—atherosclerosis	5.16e-06	5.97e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—INS—atherosclerosis	5.15e-06	5.96e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCL2—atherosclerosis	5.15e-06	5.96e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCL2—atherosclerosis	5.13e-06	5.94e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—STAT3—atherosclerosis	5.12e-06	5.93e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCL2—atherosclerosis	5.12e-06	5.92e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IGF1—atherosclerosis	5.07e-06	5.87e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MAPK8—atherosclerosis	5.07e-06	5.87e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCL2—atherosclerosis	5.07e-06	5.86e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—GPX1—atherosclerosis	5.07e-06	5.86e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IGF1—atherosclerosis	5.06e-06	5.86e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling by GPCR—AKT1—atherosclerosis	5.06e-06	5.85e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IGF1—atherosclerosis	5.05e-06	5.84e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IGF1—atherosclerosis	5.03e-06	5.82e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—atherosclerosis	4.99e-06	5.77e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IGF1—atherosclerosis	4.98e-06	5.76e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—MTHFR—atherosclerosis	4.96e-06	5.74e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CD36—atherosclerosis	4.93e-06	5.71e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MAPK3—atherosclerosis	4.9e-06	5.66e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	4.9e-06	5.66e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—VEGFA—atherosclerosis	4.89e-06	5.66e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARA—atherosclerosis	4.87e-06	5.63e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—STAT3—atherosclerosis	4.84e-06	5.6e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	4.82e-06	5.57e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—HMOX1—atherosclerosis	4.81e-06	5.56e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	4.81e-06	5.56e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	4.79e-06	5.54e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	4.78e-06	5.53e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TGFB1—atherosclerosis	4.75e-06	5.5e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	4.73e-06	5.47e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AGT—atherosclerosis	4.71e-06	5.45e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	4.7e-06	5.44e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	4.68e-06	5.42e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.68e-06	5.41e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NOS3—atherosclerosis	4.67e-06	5.41e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—STAT3—atherosclerosis	4.63e-06	5.36e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	4.62e-06	5.35e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—APOE—atherosclerosis	4.62e-06	5.34e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOB—atherosclerosis	4.61e-06	5.33e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NOS3—atherosclerosis	4.6e-06	5.32e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NOS3—atherosclerosis	4.59e-06	5.31e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARA—atherosclerosis	4.59e-06	5.31e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—CAV1—atherosclerosis	4.58e-06	5.29e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NOS3—atherosclerosis	4.57e-06	5.29e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—APOA1—atherosclerosis	4.57e-06	5.28e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NOS3—atherosclerosis	4.56e-06	5.28e-05	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	4.54e-06	5.25e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NOS3—atherosclerosis	4.52e-06	5.22e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	4.49e-06	5.19e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.48e-06	5.19e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—IL6—atherosclerosis	4.47e-06	5.17e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AGT—atherosclerosis	4.44e-06	5.14e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	4.43e-06	5.12e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—LPL—atherosclerosis	4.4e-06	5.09e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOE—atherosclerosis	4.35e-06	5.04e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—CAV1—atherosclerosis	4.31e-06	4.99e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOA1—atherosclerosis	4.3e-06	4.98e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	4.3e-06	4.97e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—GPX1—atherosclerosis	4.29e-06	4.97e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—atherosclerosis	4.25e-06	4.92e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	4.2e-06	4.86e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CD36—atherosclerosis	4.18e-06	4.84e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.17e-06	4.82e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CXCL8—atherosclerosis	4.15e-06	4.8e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	4.13e-06	4.78e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	4.12e-06	4.77e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	4.08e-06	4.72e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CXCL8—atherosclerosis	4.07e-06	4.71e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	4.06e-06	4.69e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	4.04e-06	4.68e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARG—atherosclerosis	4.02e-06	4.65e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	4.01e-06	4.63e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	4.01e-06	4.63e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.96e-06	4.58e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—INS—atherosclerosis	3.95e-06	4.57e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—IL6—atherosclerosis	3.94e-06	4.56e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	3.94e-06	4.56e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.93e-06	4.55e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.93e-06	4.54e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	3.92e-06	4.54e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	3.91e-06	4.52e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARA—atherosclerosis	3.89e-06	4.5e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—IL6—atherosclerosis	3.88e-06	4.49e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—IL6—atherosclerosis	3.87e-06	4.48e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	3.87e-06	4.48e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—IL6—atherosclerosis	3.86e-06	4.46e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—IL6—atherosclerosis	3.85e-06	4.45e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	3.82e-06	4.41e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—IL6—atherosclerosis	3.81e-06	4.41e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARG—atherosclerosis	3.79e-06	4.39e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—atherosclerosis	3.78e-06	4.37e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AGT—atherosclerosis	3.76e-06	4.35e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—atherosclerosis	3.75e-06	4.34e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—INS—atherosclerosis	3.72e-06	4.3e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NFKB1—atherosclerosis	3.71e-06	4.29e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—atherosclerosis	3.69e-06	4.27e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOE—atherosclerosis	3.69e-06	4.27e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—atherosclerosis	3.68e-06	4.26e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—atherosclerosis	3.67e-06	4.25e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—atherosclerosis	3.66e-06	4.23e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—CAV1—atherosclerosis	3.65e-06	4.23e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	3.65e-06	4.22e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK8—atherosclerosis	3.65e-06	4.22e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOA1—atherosclerosis	3.64e-06	4.22e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NFKB1—atherosclerosis	3.64e-06	4.21e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—atherosclerosis	3.64e-06	4.21e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	3.63e-06	4.2e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—atherosclerosis	3.62e-06	4.19e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	3.62e-06	4.19e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—ALB—atherosclerosis	3.62e-06	4.19e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	3.61e-06	4.18e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	3.59e-06	4.15e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	3.58e-06	4.15e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK8—atherosclerosis	3.58e-06	4.14e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—IL6—atherosclerosis	3.58e-06	4.14e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	3.58e-06	4.14e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—atherosclerosis	3.57e-06	4.13e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	3.57e-06	4.13e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	3.56e-06	4.12e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	3.56e-06	4.12e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	3.55e-06	4.11e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	3.52e-06	4.08e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	3.51e-06	4.07e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	3.5e-06	4.05e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—NOS3—atherosclerosis	3.46e-06	4e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—ALB—atherosclerosis	3.41e-06	3.94e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—IL6—atherosclerosis	3.38e-06	3.91e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—atherosclerosis	3.37e-06	3.9e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—atherosclerosis	3.33e-06	3.86e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.33e-06	3.85e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	3.31e-06	3.83e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—atherosclerosis	3.31e-06	3.83e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—atherosclerosis	3.3e-06	3.82e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	3.3e-06	3.81e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	3.29e-06	3.8e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—atherosclerosis	3.28e-06	3.8e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—atherosclerosis	3.27e-06	3.79e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—atherosclerosis	3.26e-06	3.78e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—NOS3—atherosclerosis	3.26e-06	3.77e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	3.25e-06	3.76e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—atherosclerosis	3.25e-06	3.76e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—IL6—atherosclerosis	3.24e-06	3.75e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—atherosclerosis	3.22e-06	3.73e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARG—atherosclerosis	3.21e-06	3.72e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MAPK3—atherosclerosis	3.19e-06	3.69e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—atherosclerosis	3.16e-06	3.66e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—INS—atherosclerosis	3.15e-06	3.64e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	3.13e-06	3.63e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MAPK3—atherosclerosis	3.13e-06	3.62e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—atherosclerosis	3.12e-06	3.61e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	3.12e-06	3.61e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	3.11e-06	3.6e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TGFB1—atherosclerosis	3.09e-06	3.58e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	3.08e-06	3.56e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	3.04e-06	3.52e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFB1—atherosclerosis	3.03e-06	3.51e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	3.02e-06	3.5e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	3.02e-06	3.49e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—atherosclerosis	2.99e-06	3.46e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	2.99e-06	3.45e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.98e-06	3.45e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—ALB—atherosclerosis	2.89e-06	3.34e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—NOS3—atherosclerosis	2.76e-06	3.2e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.64e-06	3.05e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.53e-06	2.92e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—atherosclerosis	2.51e-06	2.9e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—atherosclerosis	2.43e-06	2.82e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—IL6—atherosclerosis	2.33e-06	2.69e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—IL6—atherosclerosis	2.29e-06	2.65e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—IL6—atherosclerosis	2.29e-06	2.65e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—IL6—atherosclerosis	2.28e-06	2.64e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—IL6—atherosclerosis	2.27e-06	2.63e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—IL6—atherosclerosis	2.25e-06	2.6e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—atherosclerosis	2.15e-06	2.49e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—atherosclerosis	2.11e-06	2.45e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—atherosclerosis	2.11e-06	2.44e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—atherosclerosis	2.1e-06	2.43e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—atherosclerosis	2.1e-06	2.43e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—atherosclerosis	2.08e-06	2.4e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—atherosclerosis	1.59e-06	1.84e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—atherosclerosis	1.5e-06	1.73e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—atherosclerosis	1.27e-06	1.47e-05	CbGpPWpGaD
